earnings
confidence high
sentiment positive
materiality 0.70
TriSalus Q2 revenue $11.2M (+52% YoY); reaffirms 50% FY growth; net loss $9.0M
TriSalus Life Sciences, Inc.
2025-Q2 EPS reported
-$0.65
revenue$20,380,000
- Revenue $11.2M, +52% YoY, +22% sequential; gross margin 84% vs 88%.
- Operating loss improved to $7.3M from $8.2M; net loss $9.0M ($0.27 diluted EPS loss).
- Reaffirmed FY2025 revenue growth at least 50%; cash $26.5M, runway to positive adj. EBITDA H1 2026.
- Launched TriNav FLX for tortuous vessels; early sales exceeded internal projections.
- Simplified capital structure via exchange of Series A Preferred stock completed post-quarter.
item 2.02item 9.01